PPARA and metabolic dysfunction-associated steatohepatitis: It is a next-generation highly potential indole sulfonamide derivative, an anti-NASH drug, currently in the clinical trial phase III [42] designed to target and well-balanced activation of all three subtypes of PPAR shown to act on PPARα, PPARγ, and PPARδ with an EC50 value of 1.5, 0.21, and 0.87μM respectively [43].